Suzhou Ribo Life Science Co., Ltd. (HKG:6938)
Hong Kong · Delayed Price · Currency is HKD 57.05
-0.65 (-1.13%)
Sep 10, 2026, 11:59 AM HKT
Suzhou Ribo Life Science Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
| 464.43 | 148.51 | 142.63 | 0.04 | - | - | |
Revenue Growth | 157.83% | 4.13% | 324052.27% | - | - | - |
Cost of Revenue | 36.41 | 26.79 | 26.98 | 25.03 | 1.96 | 2.44 |
Gross Profit | 428.03 | 121.73 | 115.65 | -24.98 | -1.96 | -2.44 |
Selling, General & Admin | 130.27 | 119.46 | 93.49 | 81.45 | 25.43 | 18.53 |
Research & Development | 348.92 | 280.46 | 280.37 | 315.76 | 112.68 | 90.48 |
Other Operating Expenses | 65.18 | 1.13 | 0.13 | 0.01 | 0.13 | 0.05 |
Operating Expenses | 545.55 | 401.05 | 373.99 | 397.51 | 138.43 | 109.12 |
Operating Income | -117.52 | -279.32 | -258.34 | -422.49 | -140.39 | -111.57 |
Interest Expense | -22.69 | -21.44 | -20.4 | -19.19 | -1.95 | - |
Interest & Investment Income | 12.27 | 2.24 | 2.52 | 4.91 | 1.05 | 2.86 |
Earnings From Equity Investments | - | - | - | -0.02 | - | -3.89 |
Currency Exchange Gain (Loss) | - | - | 2.35 | 0.18 | 0.23 | 0.26 |
Other Non Operating Income (Expenses) | 1.84 | 0 | 0.02 | 25.73 | -0.03 | -0.02 |
EBT Excluding Unusual Items | -126.11 | -298.52 | -273.85 | -410.88 | -141.08 | -112.36 |
Gain (Loss) on Sale of Investments | - | - | - | 0.24 | - | - |
Gain (Loss) on Sale of Assets | -0 | -0.01 | - | - | -0 | -0.01 |
Asset Writedown | - | - | - | -26.51 | -0.02 | -0 |
Other Unusual Items | 13.97 | 13.97 | 16.8 | - | 6.44 | 13.1 |
Pretax Income | -112.14 | -284.56 | -257.05 | -437.15 | -134.67 | -99.27 |
Income Tax Expense | 55.11 | 3.9 | 24.45 | 0.15 | - | - |
Earnings From Continuing Operations | -167.24 | -288.45 | -281.49 | -437.3 | -134.67 | -99.27 |
Minority Interest in Earnings | -2.4 | 10.4 | 11.34 | 8.95 | 0.31 | 0.61 |
Net Income | -169.64 | -278.06 | -270.15 | -428.35 | -134.35 | -98.66 |
Net Income to Common | -169.64 | -278.06 | -270.15 | -428.35 | -134.35 | -98.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 151 | 132 | 129 | 128 | 30 | 27 |
Shares Outstanding (Diluted) | 151 | 132 | 129 | 128 | 30 | 27 |
Shares Change | 16.57% | 2.55% | 0.19% | 330.71% | 10.22% | 10.39% |
EPS (Basic) | -1.12 | -2.11 | -2.10 | -3.34 | -4.51 | -3.65 |
EPS (Diluted) | -1.12 | -2.11 | -2.10 | -3.34 | -4.51 | -3.65 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
Free Cash Flow | - | -290.58 | -84.04 | -327.53 | -144.63 | -111.39 |
Free Cash Flow Per Share | - | -2.20 | -0.65 | -2.55 | -4.85 | -4.12 |
Gross Margin | 92.16% | 81.96% | 81.09% | - | - | - |
Operating Margin | -25.30% | -188.08% | -181.13% | -960211.36% | - | - |
Profit Margin | -36.53% | -187.23% | -189.41% | -973520.46% | - | - |
Free Cash Flow Margin | - | -195.66% | -58.92% | -744395.46% | - | - |
EBITDA | -80.16 | -241.69 | -219.49 | -379.43 | -121.55 | -95.33 |
EBITDA Margin | -17.26% | -162.74% | -153.89% | - | - | - |
D&A For EBITDA | 37.36 | 37.64 | 38.84 | 43.06 | 18.83 | 16.24 |
EBIT | -117.52 | -279.32 | -258.34 | -422.49 | -140.39 | -111.57 |
EBIT Margin | -25.30% | -188.08% | -181.13% | - | - | - |